ESE vs. TVTX

Last updated Jun 9, 2026

ESE (ESCO Technologies Inc.) and TVTX (Travere Therapeutics, Inc.) are both stocks. ESE operates in Scientific & Technical Instruments (Technology), while TVTX operates in Biotechnology (Healthcare). Over the past 10 years, ESE returned 22.38%/yr vs 10.47%/yr for TVTX. At a 0.23 correlation, their price movements are largely independent.

Performance

ESE vs. TVTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ESCO Technologies Inc. (ESE) and Travere Therapeutics, Inc. (TVTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ESE achieves a 51.28% return, which is significantly higher than TVTX's 23.21% return. Over the past 10 years, ESE has outperformed TVTX with an annualized return of 22.38%, while TVTX has yielded a comparatively lower 10.47% annualized return.

ESE

• 1D: 0.94%
• 1M: -2.55%
• YTD: 51.28%
• 6M: 49.13%
• 1Y: 60.70%
• 3Y*: 45.43%
• 5Y*: 26.97%
• 10Y*: 22.38%

TVTX

• 1D: 2.77%
• 1M: 10.52%
• YTD: 23.21%
• 6M: 37.30%
• 1Y: 207.31%
• 3Y*: 41.35%
• 5Y*: 25.91%
• 10Y*: 10.47%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ESE vs. TVTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ESE ESCO Technologies Inc.	51.28%	46.96%	14.15%	34.13%	-2.30%	-12.59%	12.01%	41.00%	10.04%	6.79%
TVTX Travere Therapeutics, Inc.	23.21%	119.35%	93.77%	-57.25%	-32.25%	13.89%	91.94%	-37.25%	7.40%	11.30%

Correlation

The correlation between ESE and TVTX is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.20
Correlation (10Y) Calculated over the trailing 10-year period	0.24
Correlation (All Time) Calculated using the full available price history since Nov 9, 2012	0.23

Fundamentals

Market Cap ESE : $7.65B TVTX : $4.33B
EPS ESE : $11.89 TVTX : -$0.49
PS Ratio ESE : 6.13 TVTX : 8.20
PB Ratio ESE : 4.77 TVTX : 43.81
Total Revenue (TTM) ESE : $1.25B TVTX : $536.20M
Gross Profit (TTM) ESE : $271.43M TVTX : $385.20M
EBITDA (TTM) ESE : $238.72M TVTX : $11.15M

Return for Risk

ESE vs. TVTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ESE

ESE Risk / Return Rank: 87
ESE Sharpe Ratio Rank: 89
ESE Sortino Ratio Rank: 85
ESE Omega Ratio Rank: 84
ESE Calmar Ratio Rank: 89
ESE Martin Ratio Rank: 89

TVTX

TVTX Risk / Return Rank: 94
TVTX Sharpe Ratio Rank: 95
TVTX Sortino Ratio Rank: 95
TVTX Omega Ratio Rank: 93
TVTX Calmar Ratio Rank: 94
TVTX Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ESE vs. TVTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ESCO Technologies Inc. (ESE) and Travere Therapeutics, Inc. (TVTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ESE	TVTX	Difference
Sharpe ratio: Return per unit of total volatility	1.99	2.92	-0.93
Sortino ratio: Return per unit of downside risk	2.63	3.86	-1.23
Omega ratio: Gain probability vs. loss probability	1.33	1.48	-0.15
Calmar ratio: Return relative to maximum drawdown	4.01	6.23	-2.22
Martin ratio: Return relative to average drawdown	10.69	14.39	-3.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ESE vs. TVTX - Sharpe Ratio Comparison

The current ESE Sharpe Ratio is 1.99, which is lower than the TVTX Sharpe Ratio of 2.92. The chart below compares the historical Sharpe Ratios of ESE and TVTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ESE	TVTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.99	2.92	-0.93
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.89	0.39	+0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.74	0.18	+0.56
Sharpe Ratio (All Time) Calculated using the full available price history	0.42	0.30	+0.12

Drawdowns

ESE vs. TVTX - Drawdown Comparison

The maximum ESE drawdown since its inception was -58.54%, smaller than the maximum TVTX drawdown of -85.43%. Use the drawdown chart below to compare losses from any high point for ESE and TVTX.

Drawdown Indicators

	ESE	TVTX	Difference
Max Drawdown Largest peak-to-trough decline	-58.54%	-85.43%	+26.89%
Max Drawdown (1Y) Largest decline over 1 year	-15.22%	-33.49%	+18.27%
Max Drawdown (3Y) Largest decline over 3 years	-17.52%	-69.77%	+52.25%
Max Drawdown (5Y) Largest decline over 5 years	-36.88%	-83.12%	+46.24%
Max Drawdown (10Y) Largest decline over 10 years	-45.97%	-83.64%	+37.67%
Current Drawdown Current decline from peak	-12.95%	-1.42%	-11.53%
Average Drawdown Average peak-to-trough decline	-20.25%	-41.13%	+20.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.70%	14.49%	-8.79%

Volatility

ESE vs. TVTX - Volatility Comparison

The current volatility for ESCO Technologies Inc. (ESE) is 11.76%, while Travere Therapeutics, Inc. (TVTX) has a volatility of 14.17%. This indicates that ESE experiences smaller price fluctuations and is considered to be less risky than TVTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ESE	TVTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.76%	14.17%	-2.41%
Volatility (6M) Calculated over the trailing 6-month period	25.28%	51.90%	-26.62%
Volatility (1Y) Calculated over the trailing 1-year period	30.78%	71.68%	-40.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	30.37%	66.44%	-36.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	30.51%	58.34%	-27.83%

Dividends

ESE vs. TVTX - Dividend Comparison

ESE's dividend yield for the trailing twelve months is around 0.11%, while TVTX has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ESE ESCO Technologies Inc.	0.11%	0.16%	0.24%	0.27%	0.37%	0.27%	0.31%	0.43%	0.49%	0.40%	0.56%	0.89%
TVTX Travere Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

ESE vs. TVTX - Profitability Comparison

The chart below illustrates the profitability comparison between ESCO Technologies Inc. and Travere Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ESE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ESCO Technologies Inc. reported a gross profit of -119.92M and revenue of 309.34M. Therefore, the gross margin over that period was -38.8%.

TVTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 127.20M. Therefore, the gross margin over that period was 0.0%.

ESE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ESCO Technologies Inc. reported an operating income of 23.86M and revenue of 309.34M, resulting in an operating margin of 7.7%.

TVTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported an operating income of -36.60M and revenue of 127.20M, resulting in an operating margin of -28.8%.

ESE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ESCO Technologies Inc. reported a net income of 34.73M and revenue of 309.34M, resulting in a net margin of 11.2%.

TVTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a net income of -37.10M and revenue of 127.20M, resulting in a net margin of -29.2%.

Frequently Asked Questions

Can I hold both ESE and TVTX in my portfolio?

ESE and TVTX have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ESE or TVTX?

TVTX has higher volatility (14.17%) compared to ESE (11.76%). In terms of maximum drawdown, ESE dropped -58.54% vs TVTX's -85.43%.

Which has better risk-adjusted returns?

TVTX currently has the higher Sharpe Ratio (2.92 vs 1.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.